bimekizumab,adalimumab
ucb pharmaceuticals,abbvie
['be-optimal', 'bimekizumab', 'psoriatic arthritis']
late breaking at #acr22 phase 3 be-optimal trial shows that bimekizumab (il-17a and f mab) remains efficacious and well tolerated to week 52 in biological dmard-na ve patients with psoriatic arthritis 
The #LancetRheumatology is a clinical #rheumatology journal publishing innovative & practice-changing research & opinion across all #rheumatic & #MSK disorders